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Abstract
The family Picornaviridae contains well-known human pathogens (e.g., poliovirus, coxsackievirus, rhinovirus, and
parechovirus). In addition, this family contains a number of viruses that infect animals, including members of the genus
Cardiovirus such as Encephalomyocarditis virus (EMCV) and Theiler’s murine encephalomyelits virus (TMEV). The latter are
important murine pathogens that cause myocarditis, type 1 diabetes and chronic inflammation in the brains, mimicking
multiple sclerosis. Recently, a new picornavirus was isolated from humans, named Saffold virus (SAFV). The virus is
genetically related to Theiler’s virus and classified as a new species in the genus Cardiovirus, which until the discovery of
SAFV did not contain human viruses. By analogy with the rodent cardioviruses, SAFV may be a relevant new human
pathogen. Thus far, SAFVs have sporadically been detected by molecular techniques in respiratory and fecal specimens, but
the epidemiology and clinical significance remained unclear. Here we describe the first cultivated SAFV type 3 (SAFV-3)
isolate, its growth characteristics, full-length sequence, and epidemiology. Unlike the previously isolated SAFV-1 and -2
viruses, SAFV-3 showed efficient growth in several cell lines with a clear cytopathic effect. The latter allowed us to conduct a
large-scale serological survey by a virus-neutralization assay. This survey showed that infection by SAFV-3 occurs early in life
(.75% positive at 24 months) and that the seroprevalence reaches .90% in older children and adults. Neutralizing
antibodies were found in serum samples collected in several countries in Europe, Africa, and Asia. In conclusion, this study
describes the first cultivated SAFV-3 isolate, its full-length sequence, and epidemiology. SAFV-3 is a highly common and
widespread human virus causing infection in early childhood. This finding has important implications for understanding the
impact of these ubiquitous viruses and their possible role in acute and/or chronic disease.
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Introduction
Recent advances in molecular detection methods (e.g. viral
oligonucleotide microarrays and viral metagenomics approaches)
have led to the identification of many new viruses which are
detected not only in symptomatic, but equally in individuals
without any clinical manifestation. Insight into the potential role of
these so-called ‘‘orphan’’ viruses in disease requires a detailed
understanding of their genetic diversity and epidemiology.
Classically, the association of an infectious agent with disease
had to fulfill Koch’s postulates, a concept that is no longer tenable
in modern times. The clinical outcome of a virus infection may
depend upon the conditions under which the infection is acquired:
For example, poliomyelitis was seldom observed under conditions
of poor sanitation, congenital rubella syndrome is a consequence
of postponed childhood infection and some types of cancer are late
events in which certain viruses play a crucial role. Moreover, it
requires detailed insight in viral diversity, since it is well known
that minor differences in the genetic make-up of viruses can cause
major differences in their pathogenicity. The latter holds especially
for RNA viruses such as the picornaviruses which due to their high
mutation and recombination rates show remarkable genetic
plasticity which may lead to serious pathology merely by accident
[1].
The family Picornaviridae is one of the largest RNA virus families
[reviewed in ref. 2], containing 8 established and 6 proposed
genera and at almost 33 species. Four genera contain clinically
important viruses infecting humans, i.e. Enterovirus (which since
recently also includes the human rhinoviruses), Parechovirus,
Hepatovirus, and Kobuvirus. This family also contains economically
important animal pathogens such as Foot-and-mouth-disease virus,a
species belonging to the Aphthovirus genus. Other well-known
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(EMCV), two species that belong to the Cardiovirus genus and are
associated with disease in rodents and swine. The Theilovirus
species is represented by Theiler’s murine encephalomyelitis virus
(TMEV) and rat encephalomyelitis virus (also called Theiler’s rat
virus, TRV). TMEV is an enteric pathogen that primarily causes
asymptomatic infections of the alimentary tract. However, extra-
intestinal infection can occur and produce acute fatal encephalo-
myelitis or a chronic demyelinating disease relevant for multiple
sclerosis, depending on the TMEV strain involved [3]. TMEV can
furthermore cause serious foetal pathology and placental damage,
depending on the gestational phase of infection [4].
The question of whether authentic human cardioviruses exist
has remained unclear for a long time. A Theiler’s-like cardiovirus,
named Vilyuisk human encephalomyelitis virus (VHEV), has been
implicated in an outbreak of a neurodegenerative disease among
the Yakuts people in Vilyuisk, Siberia, in the 1950s. However, this
virus, which was isolated upon multiple passages in mice and cell
cultures, shows close relationship with TRV and TMEV, raising
the possibility that it represents a contaminating animal cardio-
virus [5]. Recently, however, strong evidence has been obtained
for the existence of human cardioviruses. In 2007, the genomic
sequence was reported of a cardiovirus, provisionally named
Saffold virus (SAFV), amplified in cell culture from the stool of an
infant presenting with fever of unknown origin in 1981 [6].
Following this discovery, SAFVs were detected by molecular
techniques in nasopharyngeal aspirates of 3 children with
respiratory symptoms in Canada [7], in stool samples from 6
paediatric patients suffering from gastroenteritis from Germany
and Brazil [8], and in 1 respiratory secretion from a patient
presenting with an influenza-like illness and 6 stool specimens from
patients in a gastroenteritis cohort in California [9]. Recently,
SAFVs were detected in stool samples from 6 South Asian children
with non-polio acute flaccid paralysis (AFP), but also in stool
samples from 5 children without overt neurological symptoms
[10]. All SAFVs identified to date are significantly divergent from
the documented animal cardioviruses, especially in the region
encoding the structural capsid proteins that are important for
receptor binding. Phylogenetic analysis suggests the existence of 8
distinct genetic SAFV lineages [10,11]. Together, these findings
suggest that SAFVs are genuine human viruses that can be
sporadically found in fecal and respiratory specimens of children,
with or without symptomatology, but that until recently have gone
largely undetected most likely because of their fastidious growth
[6,7]. Thus, their relationship with clinical disease remains to be
established.
Here we report the first isolation, full-length sequence,
characterization, and epidemiology of a SAFV-3 isolate. Evidence
is provide that this SAFV is a ubiquitous human virus causing
infection early in life. The implications of this finding for
understanding its biology and possible associations with disease
are discussed.
Results
Virus isolation and identification
In December 2007, a virus was isolated from a stool sample
obtained from a 13 month-old boy who presented with vomiting.
The sample was routinely sent in to exclude viral gastro-enteritis
but the complaints were not due to an infection but to an
anatomical mal-position of the jejunum. Culture on human
embryonic lung fibroblasts (HELF) and tertiary monkey kidney
cells (tMK) yielded a virus that was acid-stable, chloroform
resistant and that by electron microscopy showed the size
(approximately 30 nm) typical of a picornavirus (data not shown).
However, the virus isolate could not be typed as an enterovirus or
parechovirus.
To identify and characterize the unknown virus, which was
provisionally named NL2007, the tMK isolate was propagated on
HeLa cells and the virus was partially purified by centrifugation
through a sucrose cushion. Nucleic acids were isolated from the
pellet, reverse transcribed and amplified using a random PCR
method. PCR fragments were cloned and sequenced. Based on a
sequence comparison (BLASTn search), the virus was identified as
a SAFV [11].
Complete genome sequencing and phylogenetic analysis
A full genomic sequence was obtained by a genome walking
method on amplified, partially overlapping fragments of 1 to
1.5 kb. The sequence of the end of the 59 UTR was determined
using a 59-RACE amplification protocol. The genome contained a
59 UTR of 1,042 nucleotides (nt), an open reading frame (ORF) of
6,888 nt, and a 39 UTR of 121 nt followed by a poly(A) tail
(GenBank accession number FM207487).
Alignments and phylogenetic analyses were performed with
available SAFV sequences (which do not include those of the
recently identified SAFV-4 to -8 genotypes [10], which have not
yet been published). Alignment of the sequence of isolate NL2007
with other full-length cardiovirus sequences showed high sequence
similarity with SAFV-1 [6] and SAFV-2 (UC1) [9] in the 59UTR,
the regions encoding the nonstructural proteins (i.e. the leader
protein and the P2 and P3 region proteins), and the 39UTR. Less
similarity was observed in the capsid coding P1 region (Fig. 1).
The overall nt identity with TMEV, TRV, and VHEV was
considerably lower.
Phylogenetic analysis of the available VP1 coding regions
revealed six clades: TMEV, TRV, VHEV, SAFV-1, SAFV-2, and
SAFV-3 (Fig. 2). Similar clades were recovered upon phylogenetic
analysis of the available P1 protein sequences (data not shown).
Our NL2007 strain represents a new member of the SAFV-3
lineage, to date containing only P1 sequences of 2 German strains
[8] and VP1 sequences of 2 American strains [9]. Herewith, NL
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Recently, a new picornavirus was isolated from humans,
named Saffold virus (SAFV). Picornaviruses are small RNA
viruses with poliovirus as prototype. Saffold virus is
genetically related to Theiler’s virus, a member of the
Cardiovirus genus, which until this recent discovery did not
contain human viruses. Theiler’s virus is an important
mouse pathogen that causes chronic inflammation in the
brains, closely resembling multiple sclerosis in humans. By
analogy, SAFV may be a relevant human pathogen. Thus
far, SAFVs have been sporadically detected by molecular
techniques in respiratory and fecal specimens, but the
epidemiology and clinical significance have remained
unclear. Here we describe the first SAFV type 3 (SAFV-3)
isolate, its growth characteristics in cell lines, full-length
RNA-sequence, and epidemiology. Unlike the previously
isolated SAFV-1 and SAFV-2, SAFV-3 grows well in cell lines,
resulting in cell damage. This feature enabled us to
conduct a large-scale serological survey for virus-neutral-
izing antibodies. This survey showed that SAFV-3 infection
occurs early in life and that .90% of children .2 years and
adults had antibodies. Neutralizing antibodies were found
in serum samples collected in several countries in three
continents. Hence, we concluded that SAFV-3 is a genuine
and widespread human virus causing infection early in life.
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first complete SAFV-3 genomic sequence: SAFV-3(NL2007).
Molecular characteristics of SAFV-3(NL2007) and
comparison with other cardioviruses
The genetic organization of SAFV-3(NL2007) is similar to that
of the other cardioviruses [reviewed in ref. 9]. The nt and amino
acid (aa) identities of the UTRs and the individual viral proteins
with other Theiloviruses are shown in Table S1.
The 59 and 39 UTRs of SAFV-3(NL-2007) are highly conserved
to those of SAFV-1 and -2 (90 and 97% nt identity, respectively).
The 59 UTR contains a type II IRES typical for the cardioviruses.
Secondary structures of the RNA replication elements in the
UTRs, as predicted by MFOLD [12], resemble those in the other
Theiloviruses (data not shown). All picornaviruses contain an
additional higher-order RNA structure, the cis-acting replication
element (CRE), involved in uridylylation of the peptide primer,
VPg [13]. TMEV contains a CRE within the VP2 encoding
region [14]. Alignment of the available cardiovirus sequences
revealed the presence of a CRE within the same region of the
SAFVs (Fig. S1). RNA structure prediction showed a structural
element similar to that of TMEV [14].
The leader (L) protein, an interferon antagonist [15,16], is the
least conserved non-structural protein (78–80% nt identity, 82–
83% aa identity). However, the typical characteristics of the
cardiovirus L protein - i.e. a zinc-finger motif, an acidic region and
a serine/threonine-rich domain - are well conserved (Fig. S2A).
As in SAFV-1 and -2, the serine/threonine-rich domain is partially
deleted. TMEV also contains an alternative open reading frame
(ORF) encoding L* [15], a 156 aa protein associated with
neurovirulence and persistent infection [17,18]. The correspond-
ing alternative ORF in SAFV-1 and -2 encodes severely truncated
L* proteins of only 57 aa and 34 aa, respectively. SAFV-3, like
SAFV-2, contains a truncated L* protein of only 34 aa (Fig. S2B).
Whether the SAFV L* proteins are produced and have any
function remains to be shown.
The overall nt identity in the P2 and P3 regions to SAFV-1 and
-2 is 82–90%. At the aa level, the P2 and P3 region proteins in the
SAFVs are even 95–100% identical. The corresponding regions of
TMEV, TRV, and VHEV were more divergent (61–90% identity
at aa level) , although the P2 and P3 region proteins of SAFVs
were more closely related to those of TRV than to those of TMEV
and VHEV. In contrast to the high similarity for P2 and P3,
SAFV-3(NL2007) differs significantly from SAFV-1 and SAFV-2
in the P1 region. The divergence is highest in VP1 (64–69% nt
identity, 68–73% aa identity) and VP2 (71–72% nt identity, 77–
79% aa identity) and lowest in VP4 region (82–84% nt identity,
99–100% aa identity), which is located at the interior of the capsid.
The identity of SAFV-3(NL2007) with the Germany SAFV-3
Figure 1. Similarity plot analysis based on complete cardiovirus sequences using SAFV-3 (NL2007) as query sequence. Analysis made
use of a sliding window of 200 bases and a step size of 20 bases. The y-axis shows the percentage of similarity between the selected cardiovirus
sequences and the query sequence.
doi:10.1371/journal.ppat.1000416.g001
Seroprevalence of Saffold Virus
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with the US SAFV-3 strains (UC1 and UC5) is 86% (nt) and 97%
(aa).
Cardioviruses contain 4 small loops at their outer surface that
are important sites for recognition by neutralizing antibodies [19].
Two loops are part of the VP1 CD loop structure and 2 are part of
the VP2 EF loop structure. These loop sequences, which are the
regions of greatest divergence, are unique for each of the different
SAFVs and well-conserved among different strains belonging to a
specific SAFV genotype. Comparison of the CD and EF loop
structures confirmed the close relationship of the NL2007 virus
with the 2 German and the 2 US SAFV-3 sequences (Fig. 3).
Remarkably, SAFV-3(NL2007) contains a unique aa substitution
(lysine instead of alanine) in VP1 CD loop-II.
Virus replication characteristics
Thus far, SAFVs have been shown difficult to propagate on cell
lines. Only two SAFVs have been propagated in cell culture, a
SAFV-1 in human fetal diploid kidney (HFDK) cells [6] and a
SAFV-2 in rhesus monkey kidney cells (LLC-MK2) [7]. Both
viruses were reported unable to replicate on many other cell lines.
As described above, the SAFV-3(NL2007) virus was isolated on
HELF and tMK cells and passaged on HeLa cells (a human
epithelial cervical carcinoma cell line), on which the virus
produced a rapid cytopathic effect (CPE) culminating in complete
lysis of the cell monolayer. Additional studies showed replication -
as tested by end-point titration on HeLa cells - of SAFV-
3(NL2007) in rhesus monkey kidney cells (LLC-MK2), but not in
human embryonic kidney (HEK293), African green monkey
kidney (Vero), Buffalo green monkey kidney (BGMK), or
Madin-Darby canine kidney (MDCK) cells. Viral growth curves
and CPE produced on HeLa, HELF, and LLC-MK2 cells are
shown in Fig. 4A and Fig. 4B, respectively. The data show that
virus replication was most efficient in HeLa cells resulting in a
,1000-fold increase in virus titer within 24 hours and complete
lysis of the cell monolayer in 2–3 days.
Prevalence of SAFV-3 antibodies
Growth properties of SAFV-3(NL2007) with a clear CPE in
HeLa cells made it possible to conduct a serological survey by virus
neutralization (VN). A total of 210 serum samples sent to our
laboratory for routine diagnostics, were tested in the VN assay.
These included serum samples from 60 adults (females at week 12
of pregnancy) collected in 2004 and serum samples from 120
paediatric patients, of different age groups: 2, 4, 8 and 10 year of
age, 30 samples each, collected in 2006–2007. In addition, serum
Figure 2. Phylogenetic tree based on cardiovirus VP1 sequences. Sequences were analyzed as indicated in the text. Bootstrap values from
100 replicate trees are shown next to the branches. The bars represent the number of substitutions per site.
doi:10.1371/journal.ppat.1000416.g002
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were tested. At this age, serum IgG levels start to rise from a
physiological nadir and remaining maternal antibody levels are
low. As is shown in Fig. 5, 21/30 infants tested negative (titers
,1:10) and geometric mean titers of neutralizing antibodies were
lowest at the age of 9 months. Titers rose sharply between the age
of 9 months and of 2 years (p,0.0005, unpaired t-test, two-tailed).
Of 90 children between 4–10 years of age, 92% had neutralizing
antibodies against SAFV-3 and 98% of 60 adults (Fig. 5,
Table 1). Titers of neutralizing antibodies in the adults were
higher than those in the 2-year old children (p,0.05) (Fig. 5).
None of the 30 serum samples from the 2-year-old children
contained antibodies against EMCV, illustrating the specificity of
the VN assay. These results indicate that antibodies against SAFV-
3 are highly prevalent in the Netherlands and that infection most
likely occurs early in life.
Next, we investigated the prevalence of SAFV-3 antibodies in
other countries. Serum samples from 30 children from Finland
(age 24–30 months), collected in 1997–1998, were tested.
Furthermore, we tested serum samples from 72 African individuals
(from Mali and from Cameroon, collected in 2006 and 1997
respectively) and from 63 Indonesian individuals (from Java and
from Sumba, collected in 1997 and 2007 respectively). Neutral-
izing antibodies were found in 77% of Finnish children and 100%
of people living in Africa or Indonesia (Table 1), indicating that
infection with SAFV-3 has a wide spread distribution among
humans. Moreover, the presence of neutralizing antibodies in
samples collected in 1997–1998 proves that this particular virus or
a closely related one is circulating for at least 10 years.
We also investigated the possible occurrence of SAFV-3
antibodies in blood specimens from laboratory rodents. For this
purpose, we used pooled serum samples from rats, mice, hamsters,
guinea pigs, and rabbits. No antibodies were observed in the
samples from either of these rodent species. In addition, we tested
pooled serum samples from rats and mice containing high titer
antibodies to TMEV or EMCV. Again, no SAFV-3 neutralizing
antibodies were detected (data not shown). Together, these data
suggest that it is unlikely that SAFV-3 is a common virus in
Figure 3. Alignment of cardiovirus VP1 CD (A) and VP2 EF (B) loop sequences. Loop sequences are boxed (grey). SAFV-3(NL2007) amino
acids 270–338 (VP2) and 716–753(VP1) are shown.
doi:10.1371/journal.ppat.1000416.g003
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PLoS Pathogens | www.plospathogens.org 5 May 2009 | Volume 5 | Issue 5 | e1000416Figure 4. Replication of SAFV-3(NL2007) in cell lines. (A) Growth kinetics of SAFV-3(NL2007) on different cell types. Cells were infected with
SAFV-3(NL2007) at a multiplicity of infection of 10. At the indicated times, cells were subjected to three cycles of freezing and thawing, and the virus
titers were determined by endpoint titration on HeLa cells. (B) Cytopathic effect in the indicated cell lines at 3 days post infection with SAFV-
3(NL2007).
doi:10.1371/journal.ppat.1000416.g004
Figure 5. Antibody prevalence and geometric mean titers of
neutralizing antibodies against SAFV-3 in sera of 30 children 9
months of age, 30 children at the age of 2 years and 60 adult
women at week 12 of pregnancy, all from the Netherlands. *,
p,0.05; **, p,0.0005.
doi:10.1371/journal.ppat.1000416.g005
Table 1. Prevalence of neutralizing antibodies against SAFV-3
in sera from infants, young children and adults from different
countries.
Country # Samples Age range Period
1
# Positive
(%)
2
Netherlands 30 9 months 2006/2007 9 (30)
Netherlands 30 24 months 2006/2007 28 (93)
Netherlands 90 4, 8,10 yrs 2006/2007 83 (92)
Netherlands 60 18–39 yrs 2004 59 (98)
Finland 30 2–2.5 yrs 1997/1998 23 (77)
Cameroon 29 5–15 yrs 1997 29 (100)
Mali 43 10–40 yrs 2006 43 (100)
Indonesia (Java) 30 6–40 yrs 1997/1998 30 (100)
Indonesia
(Sumba)
33 5–40 yrs 2007 33 (100)
1period, blood samples were collected.
2titer$10.
doi:10.1371/journal.ppat.1000416.t001
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our neutralization assay.
Discussion
The family Picornaviridae contains a large number of notorious
human and animal pathogens. The recent identification of human
cardioviruses, Saffold viruses, has prompted studies to establish an
association between these viruses and disease. Current information
on SAFVs is almost exclusively based on molecular detection of
these viruses in respiratory and stool samples, where virus is found
at low frequency and mainly in children under 6 years of age
[7,8,9], but the clinical significance of SAFV infections is unclear.
From current data as well as from unpublished results by ourselves
and others, it appears that further molecular surveys on respiratory
and stool specimens may not readily provide an answer. For
gaining more insight into the significance of SAFVs, complemen-
tary studies are required, such as (i) serological surveys to address
the prevalence of infection, (ii) a detailed scrutiny for signs of
systemic infection (testing in blood, biopsies, etc), and (iii) analysis
of the possible implications of these viruses in terms of ecology and
integrity of the gut as major immunological border of host defense.
Here, the first serological survey of a SAFV is presented and the
possible impact of these viruses is discussed.
The serological survey was performed with a SAFV-3 isolate
that we isolated and characterized. Our SAFV-3 isolate is the first
reported SAFV that efficiently replicates in cell lines and produces
a clear cytopathic effect, thereby allowing to conduct a large-scale
survey by means of a specific virus-neutralization assay. Using the
assay, we showed that SAFV-3 is a highly common and wide-
spread human virus causing infection in early childhood: the
seroprevalence of SAFV-3 reaches high levels (.90%) in young
children and adults. Nine months after birth, maternal antibodies
have almost disappeared. In accordance, at nine months of age,
many infants that we tested were seronegative and those that had
antibody showed low titers which may still have been of maternal
origin. A steep rise was found in 2-year-old children, both in
seroprevalence and in titers, which indicates that infection occurs
frequently and early in life. It is too early to state that SAFV
infections occur before the age of 2 years because age of infection
can be influenced by periodicity of outbreaks with a particular
genotype (e.g. SAFV-3). The latter could explain why the Finnish
children in 1997/98 showed a somewhat lower seroprevalence.
Alternatively, the low population density in Finland compared to
the Netherlands may have limited the speed of circulation of the
virus. High rates of SAFV-3 antibody were furthermore found in
African countries and in Indonesia, strongly supporting that
SAFVs are ubiquitous human viruses with a global prevalence:
SAFVs have now been reported from countries in North- and
South-America, Europe, South-Asia and Africa [6–10, this study].
A high seroprevalence contrasts with the low numbers (,1%) of
respiratory and fecal samples that tested positive by PCR, at least
in developed countries [6,7]. We have no explanation for this
discrepancy. A possible explanation can be that virus is produced
and excreted only for a very brief period, limiting the chance of its
detection. However, the latter would also shorten the period of
contagiousness and virus transmission which is not in line with
ubiquity and infection early in life. The majority of SAFVs has
been detected in feces suggesting transmission by the fecal-oral
route. Fecal-oral transmission is generally associated with a
prolonged fecal excretion typically found for enteroviruses,
parechoviruses as well as rodent cardioviruses. Enteroviruses and
parechoviruses are detected 5–10 times more frequently in feces
compared to SAFVs in developed countries [20, our unpublished
data] although their epidemiology is quite similar. A higher
percentage of SAFVs (10% positive feces samples) was recently
reported in children from Pakistan and Afghanistan [10]. This
may be due to differences in sanitation, but this remains to be
established.
Another aspect of consideration is the specificity of serology.
Virus neutralization tests are highly specific and can discriminate
serotypes within a single species [21]. From the phylogenetic
analysis in this study it is unlikely that the neutralization assay with
SAFV-3(NL2007) measured antibodies that cross-react with other
genotypes, let it be with other species: The phylogenetic distinction
between SAFV genotypes is largely based on differences within the
capsid region. Known SAFV-3 strains show a high level of
conservation (cave drift) in their VP1 protein (97–98% aa identity)
but a significant level of divergence with that of SAFV-1 and -2
(68–73% aa identity), which is most probably due to immune
selective pressure. The reported divergence is analogous to that
observed in VP1 between serotypes of human enteroviruses, where
nt differences in VP1 of more than 25% or aa differences of more
than 12% are indicative of different serotypes [22–24]. The
highest variability among the different SAFVs was observed in the
VP1 CD loop and the VP2 EF loop which are located at the outer
surface of the virion and implicated as important sites for binding
of neutralizing antibodies. Given the large differences between
their VP1 proteins, it is reasonable to assume that the 8 SAFV
genotypes identified to date are serologically distinct. Accepting
that the serological data in this study regard largely, if not entirely,
one single type (SAFV-3), the contrast with sparse detection of
SAFVs by PCR is even greater and additional studies are required
to solve this discrepancy.
Our serological data are consistent with infection early in life
which is corroborated by PCR data being mainly positive in
children below 6 years of age [6–9]. In this age group, SAFVs may
be a cause of respiratory disease [7,9] and/or gastro-enteritis [8,9],
but the evidence is thin and the possibility of it being an innocent
bystander in fecal samples is not excluded. Similarly, the relevance
of SAFVs in the feces of non-polio AFP cases in South Asia
remains to be established since SAFVs were also found in
asymptomatic children [10]. Apparently, severe pathology due to
SAFV infection is rare, at least in the young, and whether it occurs
remains to be established. Importantly, not all adults that were
tested in our serological study have passed SAFV-3 infection and a
small proportion of them may thus still be susceptible (as shown in
Fig. 5 for pregnant women). Moreover, a high seroprevalence
early in life causes a severe constraint on further circulation of the
virus, which can be overcome by subtle antigenic drift, as known
for influenza viruses, resulting in re-infection at older age.
Variation in the loop sequences - as observed in the SAFV-
3(NL2007) isolate, which differs a single aa from other SAFV-3
strains in one of its VP1 loops (Fig. 3) - is in agreement with such a
drift, but whether re-infections occur remains to be proven:
Significantly higher antibody levels in adults, compared to children
(Fig. 5), may suggest so but an increase in antibody levels may also
be the consequence of infection by other members of the species
(phenomenon of the original antigenic sin, OAS) [25]. Thus, one
has to consider that adults may still be susceptible and may acquire
infection under unfavorable conditions, e.g. during pregnancy
when infection may be a threat for the fetus or newborn [4,26,27].
Although enteroviruses and parechoviruses mostly cause
asymptomatic infections, they can cause severe pathology
depending on the conditions of infection, which involve both host
determinants (e.g. age of infection, genetic background) and virus
determinants (e.g., serotype, virulence). Some good examples are
provided by the human enterovirus C (HEV-C) species which includes
Seroprevalence of Saffold Virus
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the polioviruses which can cause severe neurological disease and
paralysis [2]. Virulence of a virus variant may depend on a single
or a few amino acid substitutions as is illustrated by poliovirus type
3 Sabin, the vaccine strain, which differs from the parental strain
in not more than 3 aa [28]. Similarly, SAFV as species may
comprise a whole spectrum of variants, including variants that
cause pathology dependent on the conditions of infection and the
virus type and/or strain involved. For the two animal species of
Cardiovirus there is robust evidence that such variations exists. A
single point mutation, resulting in a change in amino acid within
the VP1 capsid region, is sufficient to transform EMCV from wild
type into a diabetogenic phenotype in mice [29]. TMEV strains
are divided into two sublineages according to the pathology they
cause in the central nervous system of susceptible mice. Highly
neurovirulent strains (e.g. GDVII) cause an acute and lethal
encephalomyelitis. Low neurovirulent strains (e.g. DA) cause a
mild, transient encephalitis that is followed by viral persistence in
the spinal cord white matter, resulting in a chronic inflammatory
response and lesions of primary demyelination, highly similar to
the signs and symptoms observed in Multiple Sclerosis [2,3]. The
difference in pathology caused by these TMEV strains reflects
most likely a difference in neural tropism in the brains due to a
difference in coreceptor usage [30]. Different SAFVs may also
exhibit a difference in tropism. Consistent with this, we found a
difference in tropism between our SAFV-3 isolate and a SAFV-2
that was isolated in our lab. This latter virus could be propagated
on LLC-MK2 cells, albeit poorly, consistent with the growth
pattern of SAFV-2 Can112051 on this cell type [7], but failed to
replicate on HeLa or HELF cells (data not shown). The intriguing
possibility of involvement of SAFV in MS awaits further
investigation. The search for implications of SAFV infections is
just starting and as depicted before, it may require testing for
systemic infection, e.g. in blood, cerebrospinal fluid or biopsies of
affected organs (e.g. brains). Results for cerebrospinal fluid
specimens have been reported, but so far with a negative outcome
[9]. Hence, the human cardioviruses are currently orphan viruses
as were ECHO viruses in the past.
New molecular approaches have rapidly expanded the list of
enteric viruses (e.g. SAFV, Cosa virus, Boca virus) for which
pathology is currently less evident [31,32]. Moreover, the increased
sensitivity of nucleic acid-based techniques confronts the physician
with a relatively new phenomenon of co-infection with 2, 3, or even
more viruses at a time, making ithard to predictwhich of these is the
culprit, if causing pathology at all. The latter holds not only for these
new viruses but also for well known pathogens as enterovirus,
parechovirus and adenovirus. Herewith, a picture emerges of a ‘viral
flora’ quite similar to the microbiome of intestinal resident bacteria
which are largely beneficial to the host, e.g. by competing out
pathogenic invaders and playing an active role in shaping an
intestinal immune barrier [33,34]. A beneficial effect (cross-
protection against bacterial invaders) has also been demonstrated
for beta- and gamma-herpesviruses in mice [35]. Human cytomeg-
alovirus has probably a similar effect as it changes the T-cell system
dramatically,inducing a uniquepopulation of effector-memoryCD8
T cells with innate-response features [36,37]. Viruses, however, are -
by nature- host-cell invasive microbes (which gut-resident bacteria
are not) and a beneficial role of enteric viruses has not been
investigated. Coxsackie B viruses, and probably also other enteric
viruses, affect the tight junctions of the intestinal epithelial cells,
which are the gatekeepers of the intestine, thereby increasing gut
leakiness [38]. The latter is a direct cause of local inflammation, it
may alter mucosal immunity in a beneficial way but leakiness has
also been associated with chronic inflammatory disease, as type 1
diabetes and celiac disease [39]. Several lines of evidence indicate a
role for coxsackie B viruses and other enteric viruses in type 1
diabetesinhumans[reviewed in40and 41]. A possible roleof SAFV
in the development of this disease should be considered in future
studies. In such studies, a role of different genotypes and, by analogy
with EMCV, different strains belonging to one genotype should be
taken into account.
In conclusion, the SAFVs, are human viruses belonging to the
genus Cardiovirus of the picornavirus family. SAFV-3, one of its
genotypes, shows a high seroprevalence on three different
continents, indicating wide-spread presence of infection among
humans. Infection by SAFV-3 is most likely acquired early in life.
Infection may pass without symptoms but the full clinical and/or
biological spectrum remains still to be established.
Materials and Methods
Viral culture and characterisation
Fecal and respiratory samples are routinely cultured on human
embryonic lung fibroblasts (HELF), tertiary monkey kidney cells
(tMK) and Hep-2 cells. Isolates with a cytopathic effect (CPE)
suggestive for a picornavirus are tested for acid- and chloroform
resistance. If so, the isolates are typed using enterovirus typing
serum pools provided by the National Institute for Public Health
and Environment, Bilthoven, The Netherlands (RIVM) [42].
When typing with serum pools provides no answer, the isolate is
genetically typed by PCR with primers specific for enterovirus,
parechovirus and rhinovirus.
Complete genome cloning and sequencing
The virus was partially purified by centrifugation through a
layer of 30% (w/w) sucrose in PBS for 3 h at 250,0006G, 4uC.
RNA was isolated from the pellet using Trizol-B (Invitrogen)
according to the protocol of the manufacturer and amplified using
a random PCR method [43]. Reverse transcription was performed
with Transcriptor RT (Roche) and subsequent PCR using the long
range PCR kit (Roche) according to the protocols of the
manufacturer. PCR fragments were cloned into the pTOPO
vector (Invitrogen) and sequenced. Based on a sequence
comparison (BLASTn search), the virus was identified as a SAFV.
A full genomic sequence was obtained by a genome walking
method on amplified, partially overlapping fragments of 1 to
1.5 kb. The 59UTR sequences were determined using the 59-
RACE System (Invitrogen) according to the manufacturer’s
protocol.
Phylogenetic analysis
Nucleotide and protein sequences of the following cardiovirus
genomes were obtained from GenBank (accession numbers): TRV
NGS910 Japan 1991 (AB090161); TRV-1 USA 2006 (EU815052);
VHEV (M80888 and EU723237); TMEV DA (M20301); TMEV
GDVII (NC_001366); SAFV-1 USA 1981 (NC_009448); SAFV-2
D2229 2004 (EU681176); SAFV-2 UC-1 2005 (EU376394);
SAFV-2 Can 2006 (AM922293); SAFV-2 BR118 2006
(EU681177); SAFV-3 D2273 2004 (EU681178); SAFV-3 D2223
2004 (EU681179); SAFV-3 NL2007 (FM207487). Sequence
alignment was performed using ClustalW [44]. Phylogenetic trees
were constructed by Maximum Likelihood algorithm as imple-
mented in the Phylip software package version 3.67 [45].
Similarity plots were made using SimPlot version 3.5.1 [46].
Growth curves
A virus stock of SAFV-3 was produced on HeLa cells, aliquoted,
and titrated by end-point titration on HeLa cells. For growth
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multiplicity of infection (MOI) of 10 for 30 min at room
temperature. Cells were grown at 36uC for 0, 8, 24, 48 or 72 h.
At these time points, viruses were released by three cycles of
freezing and thawing. Virus titers were determined by end-point
titration on HeLa cells as previously described [47].
Virus neutralisation assay
Virus neutralisation (VN) assays were performed on human
epithelial cervical carcinoma (HeLa) cells in a microtiter assay as
described for enteroviruses [48]. Six three-fold serum-dilution
steps were used, starting at a 1:10 dilution. The highest dilution
that completely inhibited viral CPE was taken as titer. Next to
SAFV, an EMCV (strain Mengovirus) was tested for comparison.
Serum samples for virus neutralisation assay
A total of 375 serum specimens were tested, belonging to three
categories: a) routine viral diagnostic samples (n=210); b) serum
samples from 30 Finnish children collected for a surveillance study
on antibodies against polioviruses; c) samples from 135 individuals
living in two African countries and two different areas in Indonesia
collected for studies on malaria. Permission for anonymous testing
of the samples fulfilled the terms of the ethical code ‘‘Goed
Gebruik’’ of the Netherlands Federation of Medical Scientific
Societies (Federa).
Rodent serum samples have been provided by QM Diagnostics
BV. Pooled rodent sera have been used which were tested negative
for a viral annual test panel recommended by FELASA
(Federation of the European Laboratory Animal Science Associ-
ation). Sera were derived from rats, mice, hamsters, guinea pigs,
and rabbits. In addition, pooled sera from rats positive for TMEV
and sera from mice containing high titer antibodies to TMEV or
EMCV confirmed positive by ELISA and immunoblot were
tested.
Supporting Information
Figure S1 Structure and alignment of SAFV CRE. (A)
Secondary structure of the SAFV-3(NL2007) CRE as predicted
by MFOLD. (B) Alignment of cardiovirus VP2 sequences (nt
1533–1569, numbering according to SAFV-3(NL-2007)) corre-
sponding to the CRE region. Nucleotides involved in stem
formation are indicated.
Found at: doi:10.1371/journal.ppat.1000416.s001 (0.07 MB PDF)
Figure S2 SAFV L and L* proteins. (A) Sequence alignment of
the cardiovirus leader proteins. Cysteine and histidine residues
involved in the formation of the zinc-finger are shaded. The zinc-
finger-, acidic-, and the serine/threonine-rich domains are
indicated. The EMCV L protein is phosphorylated at threonine-
47. This phosphorylation site fails in TMEV and VHEV. It is
importantly to note that although all SAFVs contain a threonine at
the corresponding position, the identity of the surrounding aa
render it an unfavorable phosphorylation site. (B) Sequence
alignment of putative cardiovirus L* proteins. The first 75 aa from
the +1 frame shifted ORF are shown. Stop codons are depicted as
*. Note that the L* proteins of the TMEV-GDVII strain and the
SAFVs contain an ACG start codon.
Found at: doi:10.1371/journal.ppat.1000416.s002 (0.07 MB PDF)
Table S1 Nucleotide and amino acid (in parenthesis) identity of
SAFV-3(NL2007) UTRs and proteins to other Theiloviruses from
which full-length sequences or polyprotein coding regions are
known.
Found at: doi:10.1371/journal.ppat.1000416.s003 (0.09 MB PDF)
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